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Introduction 
Airway inflammation plays an important role in asthma 
and its measurement has greatly improved our under- 
standing of the mechanisms that underlie this disease. It can 
be assessed irectly by means of bronchoscopy through 
analysis of bronchoalveolar lavage fluid (BALF) and 
biopsies, and also through analysis of induced sputum. 
The latter method is the least invasive and can be performed 
repeatedly, allowing inflammatory processes to be mon- 
itored over time. Further non-invasive methods used to 
detect airway inflammation include the analysis of various 
components of exhaled air, in particular nitric oxide (NO). 
It has been demonstrated that inflammatory processes in 
asthma occur not only in the central airways, but also in the 
peripheral airways and lung parenchyma (1). Treatment of 
inflammation, either via the systemic or the inhaled route, 
may not reach all regions of the lung to a sufficient extent; 
therefore monitoring intlammation in different areas of the 
airways may help to optimize treatment. 
The aim of this review is to compare the different 
methods used to assess inflammation throughout the 
airways, in particular the ability to attribute the inflamma- 
tory processes to either central or peripheral airways. 
Central versus peripheral airways 
Central airways are all those down to the subsegmental 
bronchi, i.e. the fourth or fifth generation, with a diameter 
of 4-5 mm and length of 8-10 mm. Beyond this, down to 
the ninth generation, the airways have a diameter of 
2-4 mm and a length of 3-6 mm and are referred to as small 
bronchi. Airways with a diameter less than 2mm are often 
called distal or small airways, comprising terminal and 
respiratory bronchioli, down to a diameter of OSmm and 
representing the 14th to 16th generation (2). 
Bronchoalveolar lavage 
The method of bronchoalveolar lavage (BAL) was intro- 
duced in 1970. Interestingly, and in a similar way to the 
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situation experienced today with the method of induced 
sputum, it was first thought of solely as a research tool, 
owing to the difficulties in performing and standardizing 
the procedure (3,4). Nowadays, the method is well 
accepted in clinical practice as a valuable tool for 
diagnosis and monitoring of a wide range of airway and 
lung diseases (5). 
Bronchoalveolar lavage is used primarily to sample the 
alveolar region. Commonly, it is performed by sequentially 
adding four to five portions of 20-50 ml of isotonic saline to 
the middle lobe. To reduce the contribution from compo- 
nents of the peripheral airways, it is sometimes recom- 
mended to introduce the saline in larger volumes (3). 
However, it seems reasonable to deliberately investigate 
samples from the peripheral airways by recovering a first, 
small (20ml) portion of saline immediately after introduc- 
tion. The comparison of the first portion, termed bronchial 
wash (BW), and subsequently obtained portions of BALF 
has revealed a gradient in cellular composition along the 
bronchial tree, with more neutrophils and fewer macro- 
phages in the peripheral airways compared with the alveoli 
(6,7). Using special balloon catheters it is also possible to 
temporarily isolate compartments within the central air- 
ways and to selectively sample fluid from these regions (8). 
Such studies have demonstrated that the central airways 
show a higher proportion of neutrophils than the peripheral 
airways and the alveolar region. 
A recent randomized open-label study has used BAL to 
examine the anti-inflammatory effect of two different 
preparations of the inhaled corticosteroid, beclomethasone 
dipropionate (BDP 4OOpg bd), administered via a press- 
and-breathe metered dose inhaler on cells of the peripheral 
airway (9). Alveolar macrophages were harvested using 
BAL from 28 healthy volunteers before and after a lbday 
course of inhaled BDP or placebo and then placed in 
primary culture. The two formulations of BDP that were 
compared included a chlorofluorocarbon (CFC)-free pre- 
paration, which utilized hydrofluoroalkane-134a as propel- 
lant (QVARTM, HFA-BDP, 3M Pharmaceuticals, St Paul, 
MN, U.S.A.) and a CFC-containing BDP (CFC-BDP). The 
cultured alveolar macrophages were then stimulated to 
release a key inflammatory mediator, tumour necrosis 
factor-a, through incubation with a bacterial glycolipid 
preparation. It was found that glycolipid-induced tumour 
necrosis factor-a production from the harvested alveolar 
macrophage cells was significantly reduced compared with 
baseline following HFA-BDP treatment, while treatment 
with CFC-BDP and HFA-placebo had no effect. These 
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findings suggest that alveolar deposition of inhaled HFA- 
BDP is capable of modulating the inflammatory potential 
of alveolar macrophages. This study also clearly demon- 
strates how BAL techniques can be used to investigate the 
effects of asthma treatments on inflammatory processes in 
the small airways. 
In summary, the advent of flexible bronchoscopes 
has enabled several techniques to collect samples from 
different regions of the airways. Down to the subsegmental 
bronchi the location can be precisely determined and 
visualized. Beyond this, the region sampled must be 
assigned to the peripheral airways or the alveolar space. 
The introduction of ultrathin bronchoscopes, which can 
advance further down the airways, may improve this 
situation, although currently they seem to be limited to 
visual inspection (10). Bronchoscopy has been, and will 
remain, a valuable tool to assess airway inflammation and 
has potential for direct assessment of topical anti-inflam- 
matory effects, however it is rather invasive and therefore of 
limited applicability when airway inflammation is to be 
monitored repeatedly. 
Bronchial biopsies 
Biopsies can be taken at different depths of the airways, 
from bronchial mucosal biopsies of the large airway to 
transbronchial biopsies of the peripheral airways and lung 
parenchyma. Unfortunately there is little data concerning a 
comparison of cellular composition of biopsies taken in 
different depths of the central airways. It is known that the 
variability between biopsies from the same individual is 
smaller than the variation between individuals (1 l), and this 
seems to be a prerequisite of any use of biopsies to describe 
individual patterns of inflammation. 
What is available, are comparisons between endobron- 
chial and transbronchial biopsies. These studies provided 
evidence on differences in inflammation between central 
airways versus peripheral airways and the alveolar region. 
For example, patients with nocturnal and non-nocturnal 
asthma showed higher numbers of eosinophils per volume 
of tissue in the small airway/alveolar region than in 
bronchial mucosal biopsies (12). However, of fundamental 
importance is careful discrimination between which part of 
the sample is analysed. Haley et al. demonstrated a similar 
distribution of eosinophils along the airways of patients 
with asthma, but only when the outer region of the airway, 
defined as the area between smooth muscle and alveolar 
attachment, was compared (13). The inner airway regions, 
defined as the area between basement membrane and 
smooth muscle, showed the inverse course, with higher 
numbers of eosinophils in the large as compared to the 
small airways. 
Compared with forceps biopsies, brush biopsies sample a 
larger area of the airway, but sub-basal cell structures are 
1~~s well preserved. Brush biopsies mainly comprise 
epithelial and goblet cells, and for these cell types no 
differences were observed between samples taken from the 
carina and samples taken from subsegmental bronchi (14). 
Induced sputum 
Unlike bronchoscopy, the analysis of sputum, either 
induced or spontaneously produced, is a less invasive way 
to obtain material from the airways. This method therefore 
has regained major interest as a tool to measure airway 
inflammation in large numbers of subjects or repeatedly. 
Sputum is characterized by a much higher percentage of 
neutrophils than found in BW and BALF. Therefore it is 
likely that the sputum obtained during an induction is 
derived mainly from the central airways (15). Indeed, the 
percentage of neutrophils in sputum corresponds very 
closely to those found in lavage fluid of the central airways 
(8,6). When sputum composition was compared with that 
of airway secretions sampled by bronchoscopy in the 
proximal airways, again very similar percentages of 
neutrophils were found with both techniques (16). In 
addition, the inhalation of a bolus of radiolabelled particles 
into the central airways resulted in much higher radioactive 
counts in sputum as compared to the counts when particles 
were deposited peripherally (17). 
Data from our own laboratory indicate that sequential 
sputum inductions sample different depths of the airways. 
The cellular composition changes when sputum samples 
produced during three consecutive inhalation periods are 
compared (18). The highest percentage of neutrophils 
occurred in the first sputum sample, while the lowest 
proportion occurred in the sputum that was produced 
during the third induction period (Fig. 1). At the same time 
the percentage of macrophages increased, indicating that 
the sputum originated from more peripheral airways. This 
phenomenon has also been observed when using other 
induction protocols (19,20) Additional evidence for the 
hypothesis on sequential sampling of progressively more 
peripheral airways has been supplied by Gershman et al. 
who demonstrated that the concentration of mucin 
decreased and that of surfactant increased in consecutive 
sputum samples (19). 
This change in sputum composition may be considered 
in two ways. On one hand it points out the need for 
standardization of the time of sputum induction. On the 
other hand it offers a chance to deliberately sample 
different regions of the central airways by an easy to 
perform and acceptable method. It might be of interest to 
compare the gradient in cellular composition between 
different diseases. Using a slightly different protocol we 
demonstrated that proportions of neutrophils did not 
change in patients with COPD, and that the change was 
much smaller in patients with asthma as compared to 
healthy subjects (Fig. 2) (21). 
In summary, sputum induction is a non-invasive way to 
assess inflammation within the central airways. It can be 
performed repeatedly and therefore has the advantage of 
enabling airway inflammation to be monitored, e.g. in 
response to treatment. However, as compared to the more 
invasive bronchoscopy, the analysis of sputum does not 
accurately locate the origin of the sample within the central 
airways. It may only provide a relative location by 
comparing samples produced during consecutive induction 
periods. 
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FIG. I. Mean percent cell counts in sputum for three consecutive sputum sampling periods within one induction procedure. 
The decline in the percentage of neutrophils was statistically significant in the healthy (0) and asthmatic subjects (m) 
(P < O.OOl), the pattern of change being different between groups (interaction term, P < 0.05). The increase in the 
percentage of macrophages was also statistically significant (P c 0.001). Data according to Marshall et al. (18). 
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FIG. 2. Changes in sputum composition during sputum induction in different groups of patients (21). Mean and SEM of 11 
healthy subjects, 10 patients with COPD, 11 patients with mild asthma (group 1: &agonists only), 12 patients with mild to 
moderate asthma (group 2: /&-agonists and inhaled steroids) and seven patients with moderate to severe asthma (group 3: 
inhaled and oral steroids) are given. The change in the percentage of neutrophils in sputum obtained in the two induction 
periods was significant in healthy subjects and patients with moderate asthma (**P-=0*01, *P-co-OS). 0: Inhalation period 
1; n : inhalation period 2. 
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Comparison of BALF, SW, biopsies 
and induced sputum 
A number of studies compared the data from bronchoscopy 
(BALF, BW, biopsies) and induced sputum within the same 
subjects (22-25). In most cases the result was that sputum 
composition correlated better with the composition of BW 
than with the composition of BALF, while the correlation 
between the composition of sputum and that of biopsies 
was rather weak. Since evidently these methods sample 
different regions of the airways and lung, these results seem 
plausible. 
Exhaled air 
The detection of markers of disease in exhaled air, as 
guided by the physician’s nose, has a long tradition in 
medicine. Nowadays, extremely low levels of gaseous 
components such as NO can be measured by fast analysers, 
and minute amounts of substances collected in the breath 
condensate can be quantified via enzymatic reactions. 
For most compounds detectable in the breath conden- 
sate, either volatile or non-volatile, the discussion about 
their actual concentration, their reproducibility, their origin 
within the lung or airways and their interpretation has only 
just begun. For hydrogen peroxide (HzOz), at least, the flow 
dependence of the detected concentration in breath 
condensate seemed to indicate its origin from the central 
airways (26). However, variability appeared to be high 
despite all attempts to standardize the breathing man- 
oeuvres that were required. 
So far, only the measurement of NO has been 
standardized in official guidelines (27). It is well known 
that the concentration of exhaled NO is higher in asthmatic 
patients as compared to healthy subjects (28) and that levels 
of exhaled NO are increased during late phase responses to 
allergen (29). The treatment of asthma with corticosteroids 
results in a reduction of the exhaled NO, which is very 
likely due to a down-regulation of the inducible nitric oxide 
synthase (iNOS), the enzyme thought to be responsible for 
the largest part of NO produced within the airways (30). 
Recently, however, it has also been demonstrated that 
steroids also normalize the pH value that is measured in the 
breath condensate of asthmatic patients. This is possibly an 
indication for an additional mechanism affecting the 
concentration of NO in exhaled air (31). 
As NO is produced in the nasal cavities in very high 
concentrations, exceeding the concentrations detectable in 
the lower airways by a factor of 100 to 1000, it requires 
special means to measure only the NO produced in the 
airways and lung. Commonly, patients exhale against a 
resistance to assure the closure of the velum, to exclude the 
nasal NO. This results in an accurate measurement of the 
NO originating from the lung, and the NO level measured 
at a well-defined expiratory flow rate can be used 
phenomenologically to support the diagnosis of airway 
diseases or the assessment of the effects of anti-inflamma- 
tory treatment. 
However, localization of the source of the exhaled NO 
within the lung requires a special set-up and the use of 
mathematical models for the analysis of NO signals (32- 
34). Nitric oxide could be derived from the airways or from 
the alveolar region. The latter is rather unlikely, since the 
diffusing capacity for NO in the alveoli is very high. The 
conclusion that NO is derived from the airways is 
supported by direct measurements of NO via broncho- 
scope, which showed very similar concentration as those 
detected in expired air (35). Furthermore, the NO 
concentration reaches a true plateau level during exhalation 
which is flow-dependent (Fig. 3). To explain this flow 
dependence, a two compartment lung model has been 
introduced. In this model the alveolar space is connected to 
a tube, which represents the airways, through which the air 
is exhaled. During a slow passage through the tube the air 
has much time to pick up NO, as produced in the airway 
wall, resulting in high exhaled concentrations. Conversely, 
after a fast passage there will be a lower concentration in 
the exhaled air. In addition, the diffusion of NO into the air 
depends on the concentration gradients between the airway 
wall and lumen. These relations can be expressed in a 
mathematical model that describes the values observed at 
different flow rates fairly well (33). 
As a result, the level of exhaled NO is related to the level 
of production within the airways and to certain parameters 
such as the airway diffusing capacity for NO. 
When the breathing manoeuvre includes a sudden change 
of expiratory flow rate, the model can be used to estimate 
the volume of the airways within which NO is produced 
(36). As NO is considered to be a marker for airway disease, 
this production volume might correspond to the region of 
ongoing inflammation. The measurement involves an 
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FIG. 3. The upper panel shows six different NO- 
concentration profiles obtained during exhalation of the 
same volume of air at different flow rates. In the lower 
panel the average NO concentrations of the plateau levels 
are plotted against expiratory flow rate. 
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experimental setup that allows instantaneous changes to air 
flow during exhalation. This ‘step-response’ will ideally 
result in a NO signal with two plateaux. After a sudden 
reduction in air flow there is a time-lapse before the exhaled 
NO concentration begins to rise from its initial steady state 
value. This allows the deadspace of NO production, from 
the lips to the site where NO production starts within the 
airways, to be estimated. The time needed to reach the 
second steady-state (plateau) value gives the volume in 
which NO is produced within the airways. The volumes are 
obtained by multiplying the respective times with the 
respective flow rates. 
‘We used this method in a pilot study where we compared 
2 weeks of treatment with BDP (200 ng day-‘) delivered as 
HFA-BDP or CFC-BDP from metered-dose inhalers in 15 
steroid naive patients with mild asthma (37). After HFA- 
BDP treatment there was a trend towards a decreased 
bronchial NO production volume, suggesting that future 
improvements of this novel, completely indirect and fully 
non-invasive technique might be capable of a volumetric 
assessment of the site of airway inflammation. This 
reduction in NO production volume following HFA-BDP 
treatment was correlated with a significant reduction in NO 
levels and a significant improvement in lung function. 
Summary 
Invasive methods involving bronchoscopy allow identifrca- 
tion of the site of airway inflammation, although within the 
peripheral airways further distinctions are difficult. The 
method of induced sputum refers only to the central 
airways, and the analysis of exhaled NO to the airways as a 
whole. Therefore there is still a need for more refined tools 
to asses airway inflammation. 
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